Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for reducing drug-induced liver injury

a liver injury and drug technology, applied in the field of drug-induced liver injury reduction, can solve the problems of liver failure, liver damage avoidance long-term or permanent, and so as to reduce dili is not detected, and the risk of liver injury is reduced.

Inactive Publication Date: 2019-11-14
TEN PEAKS LLC
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent provides methods for treating diseases such as autoimmune and inflammatory diseases while reducing the risk and severity of a side effect called drug-induced liver injury (DILI). The inventors found that certain genetic markers make a person more likely to develop DILI when taking infliximab. By identifying these at-risk individuals and reducing the risk of DILI, the methods help to make treatment safer for more people.

Problems solved by technology

In particular, drug-induced liver injury (DILI) is a serious ADR that can lead to acute liver failure.
Upon diagnosis of DILI, administration of the therapeutic drug that triggered the DILI is generally either reduced or discontinued, but often DILI is not detected early enough to avoid long-term or permanent liver damage, or even death.
Infliximab has been linked to many instances of liver injury, but there is no information currently available to help assess a patient population's risk of developing DILI.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for reducing drug-induced liver injury
  • Methods for reducing drug-induced liver injury
  • Methods for reducing drug-induced liver injury

Examples

Experimental program
Comparison scheme
Effect test

example 1

sis of Patients with ADR Following Exposure to Infliximab

[0185]A set of 12 samples from subjects that had been treated with infliximab and had experienced drug-induced liver injury (DILI) (hereinafter referred to as “diseased samples”) were HLA tested and compared to a set of 10,397 healthy control samples (hereinafter referred to as “healthy samples”). The healthy samples were obtained from a general population of human subjects who did not experience DILI, and who may or may not have been exposed to infliximab. Analysis of a patient's genomic HLA profile and a robust statistical analysis was performed to identify HLA alleles and / or sets of alleles that are risk factors for the development of DILI following infliximab exposure.

[0186]In the first analysis of the infliximab samples, the inventors sought to find if the proportion of diseased samples exposed to an allele varied significantly from the proportion of the healthy samples with that allele. In order to do so, for each allele...

example 2

LA Analysis of Patients with ADR Following Exposure to Infliximab

[0196]A set of 25 additional samples from subjects that had been treated with infliximab and had experienced DILI were obtained. These are referred to as “cases” here. These samples were compared to a set of 60 matched controls. The matched controls were patients who received infliximab for at least one year and did not experience DILI. The controls were matched for age, sex, ethnicity, and BMI where possible. Statistical analyses were performed to identify from these cases HLA alleles that are risk factors for the development of DILI following infliximab exposure. Significant alleles were determined using Fischer's Exact Test (FET) (p<0.05).

[0197]As a secondary comparison, the HLA profiles of the 25 cases were compared to reference populations available at www.allelefrequencies.net. For calculating population presence rates, reference list entries were found by searching for “Caucasoid” ethnic origin subjects of gold-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
body weightaaaaaaaaaa
frequencyaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and / or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application No. 62 / 668,388, filed May 8, 2018, Which is incorporated herein by reference in its entirety for all purposes.BACKGROUND[0002]Adverse drug reactions (ADRs) can occur in patients who are treated with therapeutic agents. In particular, drug-induced liver injury (DILI) is a serious ADR that can lead to acute liver failure. Upon diagnosis of DILI, administration of the therapeutic drug that triggered the DILI is generally either reduced or discontinued, but often DILI is not detected early enough to avoid long-term or permanent liver damage, or even death.[0003]Infliximab is a monoclonal antibody that inhibits tumor necrosis factor (TNF), a cytokine that is involved in inflammatory processes such as those that occur in autoimmune diseases. Infliximab is approved by the United States Food and Drug Administration (FDA) for the treatment of various autoimmune disorders including rh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/24A61K31/52A61K31/415A61K31/436A61K31/58A61K31/196A61K31/4706A61K31/5415A61K31/573C12Q1/686C12Q1/6881A61P1/16
CPCA61K31/52C07K16/241C12Q1/6881A61P1/16C12Q1/686A61K31/415A61K45/06A61K31/58A61K31/5415A61K31/4706A61K31/196A61K31/436A61K31/573C07K16/244A61P37/06C12Q1/6883C12Q2600/106C12Q2600/156G01N33/56977G01N2800/065G01N2800/52C07K2317/24
Inventor SRINIVASAN, SUNDARCHOW, CHRISTINA
Owner TEN PEAKS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com